To include your compound in the COVID-19 Resource Center, submit it here.

GCS-100: Phase I

In an open-label, dose-ranging U.S. Phase I trial in 12 patients, GCS-100

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE